Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting

Reuters

Jul 24, 2025

Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting

Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis $(PFI.NZ)$ and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum $(CCH.UK)$ for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553781207"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553781207\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553781207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553781207","market":"fut","top_or_hot":-1,"title":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis <a href=\"https://laohu8.com/S/PFI.NZ\">$(PFI.NZ)$</a> and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum <a href=\"https://laohu8.com/S/CCH.UK\">$(CCH.UK)$</a> for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEndo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis <a href=\"https://laohu8.com/S/PFI.NZ\">$(PFI.NZ)$</a> and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum <a href=\"https://laohu8.com/S/CCH.UK\">$(CCH.UK)$</a> for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL8sYHHZ:1","article_id":"2553781207","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553781207","pubTimestamp":1753356635,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting. Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis  and plantar fasciitis  at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum  for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NDOI":"Endo, Inc."},"translate_title":"Endo Inc.在美国足病医学协会会议上宣布非手术治疗足底纤维瘤病的3期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDOI":0.9},"content_text":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting\n    \n\n        Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis $(PFI.NZ)$ and plantar fasciitis (PFA) at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum $(CCH.UK)$ for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH36391) on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}